Geographical and temporal variations in clozapine prescription for schizophrenia

  title={Geographical and temporal variations in clozapine prescription for schizophrenia},
  author={Jimmi Nielsen and Rasmus R{\o}ge and Ole Schjerning and Holger Jelling S{\o}rensen and David Taylor},
  journal={European Neuropsychopharmacology},

Clozapine treatment and discontinuation in Iceland: A national longitudinal study using electronic patient records

It is estimated that only about half of the estimated population of patients with treatment-resistant schizophrenia in Iceland have ever been treated with clozapine, and nearly two thirds of patients who are prescribed clozAPine in Iceland remain on it long-term.

Differences between counties in the prescribing of clozapine.

Prescribing of clozapine varies among Norwegian counties and is not correlated with the proportion of the population who are undergoing treatment for schizophrenia in the specialist health service.

Temporal trends in clozapine use at time of discharge among people with schizophrenia at two public psychiatric hospitals in Taiwan, 2006–2017

The increase in clozapine use was accompanied by an increase in concomitant use of a second antipsychotic as augmentation during the study period, and further studies are warranted to clarify the risk/benefit of this augmentation strategy.

An association between autumn birth and clozapine treatment in patients with schizophrenia: A population-based analysis

This is the first evidence from a nationwide study suggesting a possible season-associated risk of clozapine treatment in schizophrenia and might be partially explained by early exposures such as winter flu season and low vitamin D levels.

Predictors of Nonhospitalization and Functional Response in Clozapine Treatment: A Nationwide, Population-Based Cohort Study

Living with a partner was the strongest predictor of functioning after clozapine initiation in this study, stressing the need and importance of social support during the course of the treatment independent of clinical factors.

Pathway to Clozapine Use: A Comparison Between a Patient Cohort from New Zealand and a Cohort from the United Kingdom

There is evidence that access to clozapine has improved over time in both cohorts, with a reduction in the duration between presentation and initiation of clozAPine and number of different antipsychotics trialled pre-clozapines.

Prevalence of treatment-resistant psychoses in the community: A naturalistic study

The findings suggest that TRS is common in the community mental-health team, and a large proportion of these patients have not received clozapine, and indicate that identifying and treating treatment resistance should be a focus of community services for schizophrenia.



Contrasting clozapine prescribing patterns in the east and west?

There are regional differences in the prescription patterns and daily dose requirements of clozapine in two groups of patients with schizophrenia in two different settings, suggesting that there is a need to examine these patterns more closely.

Antipsychotic use in the treatment of outpatients with schizophrenia in the VA from fiscal years 1999 to 2006.

Use of each antipsychotic newly marketed over eight years increased while use of risperidone was unchanged and use of olanzapine and the first-generation antipsychotics declined.

Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review.

Clozapine treatment was quite likely delayed for longer than is clinically desirable and this delay may have important effects on quality of life, clinical outcome, and health resource utilization.

Comparison of clozapine use in Maryland and in Victoria, Australia.

Significant differences in use and dosages of clozapine were found in two populations that were similar in diagnoses and demographic characteristics.

Increased use of antibiotics in patients treated with clozapine

Early Use of Clozapine for Poorly Responding First-Episode Psychosis

The present findings suggest that clozapine may have an important role in the early treatment of first-episode patients whose psychosis does not remit with other second-generation antipsychotics during the first months of treatment.

Use of antacid medication in patients receiving clozapine: a comparison with other second-generation antipsychotics.

The prevalence of antacid use in those taking clozapine and those receiving other second-generation antipsychotics (SGAs) in patients receiving SGA medication was compared by establishing crude odds ratio (OR) and OR adjusted for statistically significant confounding variables (ie, those shown to be associated with antacid prescribing).

An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis.

A high response rate (75%) to initial antipsychotic treatment in first-episode schizophrenia is confirmed and a subsequent trial with clozapine is clearly warranted, although it remains unclear whether outcome would be further enhanced if it were used earlier in the treatment algorithm.

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

Olanzapine was the most effective in terms of the rates of discontinuation, and the efficacy of the conventional antipsychotic agent perphenazine appeared similar to that of quetiapine, risperidone, and ziprasidone.

Psychotropic prescription practices in east Asia: looking back and peering ahead

Future studies on prescribing trends of antipsychotics and antidepressants need to focus on children, adolescent and elderly patient populations, the impact of changing prescription trends and the long-term effects on patients and their caregivers, as well as pharmacogenetic factors, which can potentially pave the way for better and more individualized prescription of psychotropic drugs in east Asia.